BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29852782)

  • 1. Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.
    Waldum HL; Sørdal Ø; Fossmark R
    Scand J Gastroenterol; 2018 Jun; 53(6):639-642. PubMed ID: 29852782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
    Brusselaers N; Wahlin K; Engstrand L; Lagergren J
    BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric carcinoids after long-term use of a proton pump inhibitor.
    Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
    Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.
    Lee L; Ramos-Alvarez I; Ito T; Jensen RT
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
    Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
    Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
    McCarthy DM
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acid suppression therapy: where do we go from here?
    Scarpignato C; Pelosini I; Di Mario F
    Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin].
    Kim BW; Lee BI; Kim HK; Cho YS; Chae HS; Lee HK; Kim HJ; Han SW
    Korean J Gastroenterol; 2009 Feb; 53(2):84-9. PubMed ID: 19237833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients.
    Qvigstad G; Arnestad JS; Brenna E; Waldum HL
    Scand J Gastroenterol; 1998 Dec; 33(12):1244-8. PubMed ID: 9930386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
    Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
    BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
    Miner PB
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of H
    Shim YK; Kim N
    Korean J Gastroenterol; 2017 Jul; 70(1):4-12. PubMed ID: 28728310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.
    Fossmark R; Jianu CS; Martinsen TC; Qvigstad G; Syversen U; Waldum HL
    Scand J Gastroenterol; 2008 Jan; 43(1):20-4. PubMed ID: 18938772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors and gastric neoplasia.
    Kuipers EJ
    Gut; 2006 Sep; 55(9):1217-21. PubMed ID: 16905689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.
    Hershcovici T; Fass R
    Drugs; 2011 Dec; 71(18):2381-9. PubMed ID: 22117130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of proton pump inhibitors for the risk of gastric cancer.
    Gao H; Li L; Geng K; Teng C; Chen Y; Chu F; Zhao Y
    Medicine (Baltimore); 2022 Dec; 101(49):e32228. PubMed ID: 36626449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for
    Cheung KS; Chan EW; Wong AYS; Chen L; Wong ICK; Leung WK
    Gut; 2018 Jan; 67(1):28-35. PubMed ID: 29089382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitors and helicobacter pylori-associated pathogenesis.
    Hagiwara T; Mukaisho K; Nakayama T; Hattori T; Sugihara H
    Asian Pac J Cancer Prev; 2015; 16(4):1315-9. PubMed ID: 25743791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease.
    Lambert R
    Aliment Pharmacol Ther; 1997 Aug; 11(4):651-62. PubMed ID: 9305472
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.